What is Wedbush’s Forecast for Zenas Biopharma Q1 Earnings?

Zenas Biopharma Inc (NASDAQ:ZBIO) – Equities researchers at Wedbush issued their Q1 2025 EPS estimates for Zenas Biopharma in a research report issued on Thursday, March 20th. Wedbush analyst M. Fan forecasts that the company will earn ($1.09) per share for the quarter. Wedbush has a “Outperform” rating and a $35.00 price target on the stock. Wedbush also issued estimates for Zenas Biopharma’s Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($4.33) EPS, Q1 2026 earnings at ($1.14) EPS, Q2 2026 earnings at ($1.15) EPS, Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.43) EPS.

Separately, Guggenheim reaffirmed a “buy” rating and set a $45.00 target price on shares of Zenas Biopharma in a report on Wednesday, March 12th.

Zenas Biopharma Price Performance

Shares of NASDAQ:ZBIO opened at $9.31 on Monday. The firm has a market cap of $389.15 million and a PE ratio of -2.62. Zenas Biopharma has a one year low of $5.83 and a one year high of $26.25.

Zenas Biopharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.